EB 103
Alternative Names: CD19-redirected ARTEMIS® T-cell therapy - Estrella Biopharma; EB-103Latest Information Update: 08 Dec 2025
At a glance
- Originator Estrella Immunopharma
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Non-Hodgkin's lymphoma
Most Recent Events
- 04 Dec 2025 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (Parenteral)
- 03 Nov 2025 Efficacy and adverse events data from a phase I/II STARLIGHT-1 in Non-Hodgkin's lymphoma released by Estrella Immunopharma
- 01 Jun 2024 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (Parenteral)